Prostate Cancer Pathologic Stage Alone Independently Predicts BCRFS
Pathologic stages T3a and T3b versus T2a were associated with 8.45 and 7.1 times increased risk of biochemical recurrence on multivariable analysis.
Only pathologic staging is independently associated with biochemical recurrence-free survival (BCRFS) following radical prostatectomy (RP) for prostate cancer, according to the findings of a study conducted in Thailand.
Virote Chalieopanyarwong, MD, and colleagues at Prince of Songkla University in Songkha, Thailand, enrolled 178 men with a mean age of 68.2 years who underwent RP. Of these, 93 patients had high-risk disease based on the D'Amico risk classification criteria. The median follow-up was 32.5 months and the median time to biochemical recurrence (BCR) was 22.3 months. The 5-year BCRFS rates were 79.8%, 79.9%, 69.9%, 35.6%, and 26.8% among patients with Gleason score 6, 3+4, 4+3, 8, and 9–10 (corresponding to Gleason grade groups 1–5), respectively, the investigators reported in the Asian Pacific Journal of Cancer Prevention (2017;18:2555-2559). On multivariable analysis, only pathologic stage T3a and T3b were independently associated with BCRFS; patients with these stages had 8.45 and 7.1 times increased risks for BCR, respectively, compared with those who had pathologic stage T2a. The researchers defined BCR as 2 consecutive rising PSA values greater than 0.2 ng/mL.
The authors noted that Thailand does not have an established policy for prostate cancer screening, so many cases presented with advanced disease.
Chalieopanyarwong V, Attawettayanon W,Kanchanawanichkul W, and Pripatnanont C. The prognostic factors of biochemical recurrence-free survival following radical prostatectomy. Asian Pac J Cancer Prev. 2017;18:2555-2559.